Category Archives: Immunology

Deciphering The Immunology Combo Avalanche – Seeking Alpha

As the nearly 800 currently ongoing studies involving anti-PD-(NYSE:L)1 agents combined with other approaches speed towards readout investors will be faced with a tough question: how precisely to interpret the overwhelming amount of data generated.

The issue took centre stage at a panel discussion at today's Sachs Associates Immuno-oncology Forum on the sidelines of the Asco meeting. It will be one of several things the industry will grapple with, though it is by now abundantly clear that there is no stopping the combo study runaway train.

That fact was illustrated in a report just published by EP Vantage, which showed that the absolute number of anti-PD-(L)1 combo trials under way - with numerous mechanistic approaches - had surged nearly fourfold since November 2015 to reach 765 in April.

Dr James Mul, from the Moffitt Cancer Center, told the Sachs conference that it was hard to imagine just how rapidly these trials were being conducted. In terms of subjects enrolled, he cited data showing that there were now over 250,000 patients in active immuno-oncology studies.

"But there will be no clear-cut direction as to where combo studies are heading until about 2019," he said. "There's still a way to go before we can make clear-cut decisions."

John Beadle, chief executive of Psioxus, whose oncolytic virus enadenotucirev is being combined with Bristol-Myers Squibb's (NYSE:BMY) Opdivo, called the expected surge of data an "exponential avalanche of information".

Still, most of these studies are too early to involve randomisation, and many are not designed to answer the simple, head-to-head question of whether A plus B is better than A or B alone. And, while it is clear than many combos will not work, what yardsticks should investors use to determine whether a combination has actually given an incremental benefit?

The panel suggested that one aspect of particular relevance should be to look at whether a study involves subjects who have already failed on a checkpoint inhibitor, or those who have shown resistance to immuno-oncology in general. Signs of efficacy in these patients would clearly be of interest.

IO-IO or back to basics?

Paul Rennert, chief executive of Aleta Biotherapeutics, who was co-chairing the panel with Dr. Mul, drilled down into the changing expectations behind the various checkpoint combination approaches.

He admitted to having been one of the people who two or three years ago had made much of the potential of combining immuno-oncology with immuno-oncology, assuming that novel targets like Ox40, GITR, Tim3, Vista and others were going to raise immune responses strongly and usher in a new wave of post-PD-(L)1 agents.

"We thought we were going to get response rates up. We're not seeing that yet," he admitted. "Perhaps it's too early."

On the other hand, perhaps it is checkpoint inhibitor combinations with more traditional approaches, such as small molecules or even simple chemotherapy, that investors should pay attention to. The surge in chemo combo studies was another key finding of the EP Vantage report.

This issue could feed into other important areas such as pharmacoeconomics: a chemo combo approach would clearly be cheaper than one combining two IO agents.

At a separate Sachs Forum discussion focused on deal-making, Timothy Herpin, head of UK transactions at Astrazeneca (NYSE:AZN), said there would likely be continued interest in non-IO mechanisms, but that these would play out in combination with an IO backbone.

Guillaume Vignin, head of IO licensing at Merck KGaA (OTCPK:MKGAF) (OTCPK:MKGAY) said it was too early to call the non-IO combo approach a trend. "But there are exciting data to be published," he said. "The two will be working together - it will not all be about IO-IO."

If one thing is certain, however, it is that data will come thick and fast, and this will affect the way deals are done. The important thing seems to be just to get deals signed to get the combos into the clinic, and generate data, as quickly as possible, said Mr. Herpin.

"Once you have data we can work through the [deal] complexity," he added.

Editor's Note: This article discusses one or more securities that do not trade on a major U.S. exchange. Please be aware of the risks associated with these stocks.

More here:
Deciphering The Immunology Combo Avalanche - Seeking Alpha

Immunoassay and Live Cell Analysis Solutions Presented at IMMUNOLOGY 2017 – SelectScience

The Annual Meeting of the American Association of Immunologists (AAI) is one of the largest annual gatherings of immunologists worldwide. This years meeting, IMMUNOLOGY 2017, held in Washington, DC, USA, saw immunologists from around the world discussing breakthroughs across the full spectrum of topics in the field, while exhibitors displayed the latest technologies for cutting edge techniques.

During the event, MilliporeSigma, a business of Merck KGaA Darmstadt, Germany, presented a range of new solutions for immunologists, including a series of T Cell multiplex assay kits for low-level cytokine detection in small samples volumes, and the CellASIC ONIX2 Microfluidics System for real-time control and manipulation of cellular environment for live cell analysis. Watch the video interviews and presentation to learn more about these innovations and how they can help to advance your immunology research.

New High-Sensitivity Immunoassays Panels Detect Picogram Level Cytokines

Robert Keith, R&D Scientist, MilliporeSigma, introduces three high-sensitivity MILLIPLEX MAP panels to help researchers detect low levels of multiple cytokines in small amounts of sample: the Human High Sensitivity T Cell Magnetic Bead Panel (in both 96-well format and a new 384-well format) and the new Mouse High Sensitivity T Cell Magnetic Bead Panel in 96-well format. Both the human and mouse high-sensitivity panels can detect picogram levels of cytokines in just 25 L of sample for up to 21 or 18 critical cytokines, respectively.

Robert Keith introduces three new high-sensitivity MILLIPLEX MAP panel

Robert Keith highlights the benefits of the new T Cell multiplex assays for immunologists

Automated Cell Culture for Dynamic Analysis of Cell Function in Real Time

Dr Amedeo Cappione, Senior Scientist, MilliporeSigma, explains how the microfluidics-based CellASIC ONIX2 System offers precise real-time control of media perfusion for cell researchers who need a highly controllable and manipulatable cellular environment and the ability to conduct semi-automated, repeatable long-term experiments while continuously collecting quantitative image-based data.

Dr Amedeo Cappione explains how the CellASIC ONIX2 System works

Excerpt from:
Immunoassay and Live Cell Analysis Solutions Presented at IMMUNOLOGY 2017 - SelectScience

New Thematic Series for BMC Immunology: Cancer Immunotherapy … – BMC Blogs Network (blog)

BMC Immunology is delighted to announce the launch of a new thematic series: "Cancer Immunotherapy and Vaccines". Here, Guest Editor Francesco Pappalardo gives an introduction to the series and discusses the progress and the difficulties faced by researchers in the field.

Professor Francesco Pappalardo 31 May 2017

Pixabay

Vaccines are the most effective and cost-efficient weapons that can be used to prevent (preventive vaccines) or cure (therapeutic vaccines) diseases caused by infectious agents or cancer cells. Usually, when one thinks about the word vaccine, the first thought that comes into the mind is related to an artificial administration of a stimulus that instructs the immune system to fight against the cause of a particular pathological state (the pathogen). However, in the case of cancer vaccines, the main view, still unknown to the majority of the people not working in the field, is represented by the exploitation of the hosts immune system to treat or prevent cancer. The idea, however, dates back decades.

In the same way a traditional vaccine works, a cancer vaccine can promote the eradication of malignant cells during their initial transformation from safe to harmful cells. This eradication process, commonly referred to as immune surveillance of tumors [1], is carried out by the immune system and, most of the time, it happens without any external intervention. Tumors are the result of a particular combination of factors related to genetic and epigenetic changes that enable immortality.

In the same way a traditional vaccine works, a cancer vaccine can promote the eradication of malignant cells during their initial transformation from safe to harmful cells.

This is not a completely undetectable process: during the transformation of a normal cell into a malignant one, foreign antigens (neo-antigens or, to be more specific, onco-antigens) are created; these should render neoplastic cells visible by the immune system that can target them for elimination. Tumors cells, like every living organisms, want, nevertheless, to live. Hence, tumors try to become resistant and invisible to immune system attacks by developing multiple resistance mechanisms that include local immune evasion, induction of tolerance and systemic interference of T cell signaling. Besides, mimicking the metaphor of Darwins natural selection, immune recognition of cancer cells enforces a selective pressure on developing ones. This favors the development of less immunogenic and more apoptosis-resistant neoplastic cells, through a mechanism well known as immune editing [2].

Due to the fact that cancer cells are particularly good at evading any action from the immune system, most anti-cancer treatments are based on other means like surgery, radiation therapy, and chemotherapy. Nowadays, however, it is clear that the various arms of the immune system play an essential role in protecting humans from cancer. After unsatisfactory efforts and explicit clinical failures, the field of cancer immunotherapy has received a significant boost, thanks mainlyto the development in 2010of an autologous cellular immunotherapy, sipuleucel-T, for the treatment of prostate cancer [3] and the approval of the anti-cytotoxic T lymphocyte-associated protein 4 (CTLA-4) antibody ipilimumab (2011) andanti-programmed cell death protein 1 (PD1) antibodies (2014) for the treatment of melanoma [4]. These achievements haverenovated the field and brought attention to the opportunities that immunotherapeutic approaches can offer [5,6].

The field of cancer immunotherapy has recently received a significant boost

Pixabay

There are still, however, some difficulties to be overcome when developing effective immunotherapy strategies against cancer. The general lack of understanding of the mechanisms of immunization, the role of dendritic cells, the ability of cancer to induce tolerance, and the identification of the most suitable antigens to use are just some examples of how the development of effective strategies is still problematic [7-10]. There are several biotechnological methodologies, based on both in silico and in vivo techniques, that study and suggest possible candidates for use in immunotherapies. However, they are not able, on their own, to quantify and analyze the immune system response globally. Moreover, there are now several computational techniques to predict T cell epitopes (and,to some extent, also B cell epitopes) [11,12]. Computational simulations may help in solving these issues, but these need to be integrated with the in vitro and in silico molecular analyses [13,14]. So, a complete computational/biological pipeline that allow the best integration of in silico, in vitro and in vivo methodologies may potentially boost and improve cancer immunotherapy development and effectiveness.

The aim of the thematic series is to bring together the latest advances in both biological and computational research, looking broadly at the basic biological aspects of immunotherapy, emerging immunotherapies (both prophylactic and preventive) and different vaccination approaches. The novel, and, at the same time, established character of computation in immunology greatly improves and speeds-up the development of novel vaccination strategies, both therapeutic and preventive, against cancer. We welcome original research, methodology, software, and database article submissions.

The deadline for submission of manuscripts is 30thNovember2017. For more information, visit the BMC Immunology website.

References

View the latest posts on the BMC Series blog homepage

By commenting, youre agreeing to follow our community guidelines.

Go here to see the original:
New Thematic Series for BMC Immunology: Cancer Immunotherapy ... - BMC Blogs Network (blog)

Dr. Sirajuddin to offer allergy, immunology services at SBAMH – Butler County Times Gazette

Dr. Iram Sirajuddin will bring a new specialty to Susan B. Allen Memorial Hospital. She is an Allergist and Immunologist, who will see patients in the SBA Clinic Augusta beginning Monday, June 5.

Dr. Sirajuddin got interested in medicine at a young age. Her father is a doctor (anesthesiologist) and she enjoyed hearing him discuss his cases with the family. She also had a cousin with a blood disorder and would sometimes accompany her to doctors appointments. She was inspired by the caring relationship between the doctor and her cousin.

Thats what drew me to medicine, Dr. Sirajuddin said.

Dr. Sirajuddin attended medical school at the 6-year program at the University of Missouri - Kansas City. She trained at St. Louis Childrens Hospital with Washington University. Her residency was in Pediatrics.

I have always loved working with children, she said. Their energy and curiosity about things is something I admire.

She rotated through different specialties during her training, and developed an interest in Allergy/Immunology.

I feel when I do my job correctly, it can help people lead their best possible lives, Dr. Sirajuddin said. Its a field where you can say you really have made a difference.

She is trained to see adults and children with seasonal and food allergies, asthma, eczema and immunodeficiencies.

She moved to Wichita in 2010 and worked for the KU Medical Center from 2010 to 2012. She took an extended maternity leave, then returned to work doing Telemedicine in 2015.

She said the Telemedicine company she worked for was focused on rural Kansas and providing services to people who didnt have easy access to the medical care they needed.

While Dr. Sirajuddin enjoyed this, she said she missed the face-to- face contact with patients.

I love seeing patients face to face and building that relationship with them in person, she said.

That made her start thinking about getting back into an office setting.

While she worked at KU, she had come to SBAMH to introduce herself to the pediatricians because she was only seeing pediatric patients at the time.

She said when she recently started looking at job opportunities, she recalled how those doctors were good to work with and seemed happy where they worked.

Read this article:
Dr. Sirajuddin to offer allergy, immunology services at SBAMH - Butler County Times Gazette

Merck’s Immunology and Cardiovascular Franchise in 1Q17 – Market Realist

A Close Look at Merck & Co.s Valuation after 1Q17 Earnings PART 7 OF 8

Merck & Co.s (MRK) immunology franchise includes the drugs Remicade and Simponi. Remicade is a drug for the treatment of inflammatory disorders. Merck markets Remicade in Europe, Russia, and Turkey. Johnson & Johnson (JNJ) has the marketing rights for Remicade in a few countries outside Europe.

Remicade revenues fell ~34.0% to $229.0 million in 1Q17 compared to $349.0 million for 1Q16. That was mainly due to the entrance of generic competitors and biosimilars following the loss of exclusivity in European markets. The drug lost its exclusivity in European markets in February 2015. Remicade revenues have fallen consistently since the loss of exclusivity, and Merck expects Remicade revenues to fall further as new patients prefer biosimilars over Remicade.

Simponi is a once-monthly drug for the treatment of certain inflammatory diseases. Merck markets Simponi in Europe, Turkey, and Russia. The revenues for Simponi fell ~2.0% to $184.0 million in 1Q17 compared to $188.0 million in 1Q16.

Mercks cardiovascular franchise includes the drugs Zetia, Vytorin, Liptruzet, and Adempas. The blockbuster drugs Zetia and Vytorin are used to lower the LDL (low-density lipoprotein) cholesterol levels in the blood.The combined revenues for these drugs fell 35.0% to $575.0 million in 1Q17 compared to $889.0 million in 1Q16.

Liptruzet reported growth in revenues to $49.0 million in 1Q17 compared to $23.0 million in 1Q16. Adempas reported revenues of $84.0 million in 1Q17 compared to $33.0 million in 1Q16.

To divest the risk, you can consider the SPDR S&P Pharmaceuticals ETF (XPH), which holds ~4.6% of its total assets in Merck & Co. XPH also holds 5.1% of its total assets in Eli Lilly (LLY), 4.6% in Johnson & Johnson (JNJ), and 4.5% in Pfizer (PFE).

See the rest here:
Merck's Immunology and Cardiovascular Franchise in 1Q17 - Market Realist

CEL-SCI Scientist Presents at AAI – IMMUNOLOGY 2017 Meeting – Business Wire (press release)

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE MKT:CVM) today announced that Daniel Zimmerman, Ph.D., Senior Vice President of Research, Cellular Immunology, presented additional data on its LEAPS rheumatoid arthritis (RA) vaccine candidates CEL-4000 and CEL-2000 at IMMUNOLOGY 2017, the annual meeting of the American Association of Immunologists (AAI), May 12 16 in Washington, D.C.

The title of his poster is Key serum cytokine markers for evaluating the efficacy of vaccine therapy in autoimmune models of rheumatoid arthritis. The abstract can be viewed online or found through the conference website at: http://www.immunology2017.org.

Dr. Zimmerman and the research team concluded that serum concentrations and ratios of key disease-related cytokines can predict therapeutic efficacy in different animal models of RA. The data showed that a reduced RA disease progression was observed in mice treated with LEAPS vaccines and was accompanied by decreased pro-inflammatory cytokines level and increased ratios of anti-inflammatory/regulatory to pro-inflammatory cytokines. Thus, a successful vaccine therapy appears to be associated with a ratio shift in favor of anti-inflammatory/regulatory cytokines. The ability to predict cytokine responses to therapy should allow for better design or choice of the appropriate immunomodulatory LEAPS vaccines and other therapies in RA.

About LEAPS

L.E.A.P.S. (Ligand Epitope Antigen Presentation System) is a CEL-SCI patented platform technology designed to stimulate antigen-specific immune responses in T-cells using synthetic peptides. LEAPS constructs physically link the antigenic peptide with a T-cell binding ligand and are delivered directly to the recipient by injection or through absorption onto mucosal surfaces, potentially enhancing T-cell responses to a particular antigen.

About CEL-SCI

CEL-SCI's work is focused on finding the best way to activate the immune system to fight cancer and infectious diseases. The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this press release, the words "intends," "believes," "anticipated," "plans" and "expects," and similar expressions, are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI's filings with the Securities and Exchange Commission, including but not limited to its report on Form 10-K and 10-K/A for the year ended September 30, 2016. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

See the original post here:
CEL-SCI Scientist Presents at AAI - IMMUNOLOGY 2017 Meeting - Business Wire (press release)

Global Cancer Immunology and Oncolytic Virology Technologies and Markets Report 2017: Market Should – PR Newswire (press release)

The scope of this report covers current cancer immunotherapy markets for most common cancers. The market segments included in this report are therapeutic monoclonal antibodies (with special focus on checkpoint inhibitors), synthetic interleukins, interferons, and colony-stimulating factors; small kinase inhibitors of cancer-related targets; protective and therapeutic cancer vaccines; and adoptive cell therapies.

This report also covers treatments that are in development for late-stage and early-stage oncolytic viruses. Detailed epidemiological information, discussion of incidence and mortality trends, overview of regulatory landscapes, and analysis of market shares for leading products and companies are also included in this report.

Report Includes

Key Topics Covered:

1: Introduction

- Goals and Objectives - Reasons for Doing This Study - Intended Audience - Scope of The Study - Information Sources for the Technology Assessment - Forecasting Methodology - Geographic Breakdown

2: Summary and Highlights

3: Overview

- Past and Present of Cancer Immunology - What is Cancer? - Treating Cancer - Challenges in Treating Cancer - Cancer and the Immune System - Immunotherapy - Towards Combination Immunotherapy - Focusing on Cell-mediated Adaptive Immunity - Fine Tuning Versus Boosting Cancer Immunity - Early Versus Advanced Stage Cancer Immunotherapy - Personalized Treatment Paradigm - Clinically Significant Types of Cancers - Future of Checkpoint Inhibitors, Cancer Vaccines, and Oncolytic Virology

4: Overview of Cancer Immunotherapy

- Immune System and Immunotherapy - Therapeutic Monoclonal Antibodies - Checkpoint Inhibitors - Biological Response Modifiers - Vaccines - Other - Expanded Information on Selected Product Candidates and Recent Regulatory Applications

5: Oncolytic Virology

6: Major Markets

- Markets for Immunotherapy Products - Markets for Oncolytic Virology Products

7: Company Profiles

- Abbvie Inc. - Adaptimmune - Aduro Biotech - Advantagene - Advaxis Immunotherapies - Amgen - Argos Therapeutics - Ariad Pharmaceuticals - Arog Pharmaceuticals - Aserta Pharmaceuticals - Astellas - Astrazeneca - Avax Technologies - Bavarian Nordic - Bayer Healthcare - Biovex - Boehringer Ingelheim - Boston Biomedical - Bristol-Myers Squibb - Cell Medica - Celldex Therapeutics - Celgene Corp. - Chugai - Cold Genesys - Daiichi Sankyo Co. - Dendreon - Dnatrix - Eisai - Eli Lilly - F Hoffmann La Roche AG - Genelux - Gilead Sciences Inc. - Glaxosmithkline Plc - Hanmi Pharmaceutical - Heat Biologics - Immune Design - Immunocellular Therapeutics Ltd. - Immunomedics Inc. - Immunovaccine Inc. - Immunovative Therapies - Incyte Ciorp. - Inovio Pharmaceuticals Inc. - Janssen Pharmaceuticals - Kadmon Pharmaceuticals Corp. - Kite Pharmaceuticals Inc. - Kyowa Hakko Kirin Co. Ltd. - Ligand Pharmaceuticals Inc. - Lion Biotechnologies - Lokon Pharmaceuticals AB - Medimmune - Merck & Co. - Merck Kgaa - Merck Serono - Medigene AG - Mirati Therapeutics - Multivir Inc. - Newlink Genetics - Northwest Biotherapeutics - Novartis Pharma Services AG - Oncolys Biopharma Inc. - Oncolytics Biotech Inc. - Oncomed Pharmaceuticals Inc. - Oncos Therapeutics Ltd. - Ono Pharmaceutical Co. - Otsuka Pharmaceutical Co., Ltd. - Pfizer Inc. - Plexxikon Inc. - Portola Pharmaceuticals Inc. - Provectus Biopharmacueticals Inc. - Psioxus Therapeutics Ltd. - Sanofi SA - Seattle Genetics - Shanghai Sunway Biotech Co. Ltd. - Shenzhen Sibiono Gentech - Sillajen Biotherapeutics Inc. - Spectrum Pharmaceuticals - Takara Bio Inc. - Takeda Co. Ltd. - Tapimmune Inc. - Targovax - Teva Pharmaceutical Industries Ltd. - TG Therapeutics Inc. - Tracon Pharmaceuticals Inc. - Transgene - VCN Biosciences - Ventirx - Verastem Inc. - Viralytics Ltd. - Virttu Biologics Ltd - Vyriad - Western Oncolytics Ltd.

For more information about this report visit http://www.researchandmarkets.com/research/fpck42/cancer_immunology

Media Contact:

Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-cancer-immunology-and-oncolytic-virology-technologies-and-markets-report-2017-market-should-reach-965-billion-by-2021-from-730-billion-in-2016-at-a-cagr-of-57---research-and-markets-300458203.html

SOURCE Research and Markets

http://www.researchandmarkets.com

More:
Global Cancer Immunology and Oncolytic Virology Technologies and Markets Report 2017: Market Should - PR Newswire (press release)

Global Immunology Partnering 2010 – 2017: Deal trends, players and financials – PR Newswire (press release)

LONDON, May 17, 2017 /PRNewswire/ -- Download the full report: https://www.reportbuyer.com/product/4882472/

Description Global Immunology Partnering 2010 to 2017 provides the full collection of Immunology disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

Trends in Immunology partnering deals Financial deal terms for headline, upfront and royalty by stage of development Immunology partnering agreement structure Immunology partnering contract documents Top Immunology deals by value Most active Immunology dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Immunology disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Immunology deals.

The report presents financial deal terms values for Immunology deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Immunology dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Immunology dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Immunology deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Immunology dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Immunology deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Immunology partnering deals by specific Immunology target announced since 2010. The chapter is organized by specific Immunology therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Immunology partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Immunology partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Immunology technologies and products.

Report scope Global Immunology Partnering 2010 to 2017 is intended to provide the reader with an in-depth understanding and access to Immunology trends and structure of deals entered into by leading companies worldwide.

Global Immunology Partnering 2010 to 2017 includes: - Trends in Immunology dealmaking in the biopharma industry since 2010 - Analysis of Immunology deal structure - Access to headline, upfront, milestone and royalty data - Access to hundreds of Immunology deal contract documents - Comprehensive access to over 3500 Immunology deal records - The leading Immunology deals by value since 2010 - Most active Immunology dealmakers since 2010

The report includes deals for the following indications: AIDS, Allergy, Anaphylactic shock, Graft versus host disease, Inflammation, Other autoimmune, Scleroderma, Systemic lupus erythematosus, plus other immunology indications.

In Global Immunology Partnering 2010 to 2017, available deals and contracts are listed by: - Headline value - Upfront payment value - Royalty rate value - Stage of development at signing - Deal component type - Technology type - Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Immunology Partnering 2010-2017 report provides comprehensive access to available deals and contract documents for over 700 immunology deals.

Analyzing actual contract agreements allows assessment of the following: - What are the precise rights granted or optioned? - What is actually granted by the agreement to the partner company? - What exclusivity is granted? - What is the payment structure for the deal? - How are the sales and payments audited? - What is the deal term? - How are the key terms of the agreement defined? - How are IPRs handled and owned? - Who is responsible for commercialization? - Who is responsible for development, supply, and manufacture? - How is confidentiality and publication managed? - How are disputes to be resolved? - Under what conditions can the deal be terminated? - What happens when there is a change of ownership? - What sublicensing and subcontracting provisions have been agreed? - Which boilerplate clauses does the company insist upon? - Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? - Which jurisdiction does the company insist upon for agreement law?

Benefits Global Immunology Partnering 2010 to 2017 provides the reader with the following key benefits: - In-depth understanding of Immunology deal trends since 2010 - Access Immunology deal headline, upfront, milestone and royalty data - Research hundreds of actual contracts between Immunology partner companies - Comprehensive access to over 750 links to actual Immunology deals entered into by the world's biopharma companies - Indepth review of Immunology deals entered into by the top 25 most active dealmakers - Benchmark the key deal terms companies have agreed in previous deals - Identify key terms under which companies partner Immunology opportunities Download the full report: https://www.reportbuyer.com/product/4882472/

About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers http://www.reportbuyer.com For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: query@reportbuyer.com Tel: +44 208 816 85 48 Website: http://www.reportbuyer.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-immunology-partnering-2010---2017-deal-trends-players-and-financials-300459424.html

SOURCE ReportBuyer

http://www.reportbuyer.com

Excerpt from:
Global Immunology Partnering 2010 - 2017: Deal trends, players and financials - PR Newswire (press release)

Home | Cancer Immunology Research

Research Articles

Elena Lo Presti, Francesca Toia, Sebastiano Oieni, Simona Buccheri, Alice Turdo, Laura Rosa Mangiapane, Giuseppina Campisi, Valentina Caputo, Matilde Todaro, Giorgio Stassi, Adriana Cordova, Francesco Moschella, Gaetana Rinaldi, Serena Meraviglia and Francesco Dieli

Cancer Immunol Res May 1 2017 5 (5) 397-407; DOI:10.1158/2326-6066.CIR-16-0348

Tumor-infiltrating lymphocytes contain T cells. In early-stage SCC tumors, T cells had antitumor properties, such as production of IFN. However, clinically advanced tumors contained many more T cells that produced IL-17 and promoted tumor growth.

See original here:
Home | Cancer Immunology Research

Immunology market to see strong growth, despite patent expiries – The Pharma Letter (registration)

The global immunology market, which covers autoimmune diseases such as rheumatoid arthritis, psoriasis,

To continue reading this article and to access exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space you need to be logged into the site and have an active subscription or trial subscription. Please loginorsubscribe in order to continue reading. Claim a week's trial subscriptionby signing up for free today and receive our daily pharma and biotech news bulletin free of charge, forever.

Original post:
Immunology market to see strong growth, despite patent expiries - The Pharma Letter (registration)